Literature DB >> 11502958

Length of stay as a source of bias in comparing performance in VA and private sector facilities: lessons learned from a regional evaluation of intensive care outcomes.

P J Kaboli1, M J Barnett, S M Fuehrer, G E Rosenthal.   

Abstract

OBJECTIVES: Compare intensive care unit (ICU) mortality and length of stay (LOS) in a VA hospital and private sector hospitals and examine the impact of hospital utilization on mortality comparisons. RESEARCH
DESIGN: Retrospective cohort study.
SUBJECTS: Consecutive ICU admissions to a VA hospital (n = 1,142) and 27 private sector hospitals (n = 51,249) serving the same health care market in 1994 to 1995. MEASURES: Mortality and ICU LOS were adjusted for severity of illness using a validated method that considers physiologic data from the first 24 hours of ICU admission. Mortality comparisons were made using two different multivariable techniques.
RESULTS: Unadjusted in-hospital mortality was higher in VA patients (14.5% vs. 12.0%; P = 0.01), as was hospital (28.3 vs. 11.3 days; P <0.001) and ICU (4.3 vs. 3.9 days; P <0.001) LOS. Using logistic regression to adjust for severity, the odds of death was similar in VA patients, relative to private sector patients (OR 1.16, 95% CI 0.93-1.44; P = 0.18). However, a higher proportion of VA deaths occurred after 21 hospital days (33% vs. 13%; P <0.001). Using proportional hazards regression and censoring patients at hospital discharge, the risk for death was lower in VA patients (hazard ratio 0.70; 95% CI 0.59-0.82; P <0.001). After adjusting for severity, differences in ICU LOS were no longer significant (P = 0.19).
CONCLUSIONS: Severity-adjusted mortality in ICU patients was lower in a VA hospital than in private sector hospitals in the same health care market, based on proportional hazards regression. This finding differed from logistic regression analysis, in which mortality was similar, suggesting that comparisons of hospital mortality between systems with different hospital utilization patterns may be biased if LOS is not considered. If generalizable to other markets, our findings further suggest that ICU outcomes are at least similar in VA hospitals.

Entities:  

Mesh:

Year:  2001        PMID: 11502958     DOI: 10.1097/00005650-200109000-00011

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  6 in total

Review 1.  The evolving science of quality measurement for hospitals: implications for studies of competition and consolidation.

Authors:  Patrick S Romano; Ryan Mutter
Journal:  Int J Health Care Finance Econ       Date:  2004-06

2.  The revised Atlanta criteria more accurately reflect severity of post-ERCP pancreatitis compared to the consensus criteria.

Authors:  Xjnm Smeets; N Bouhouch; J Buxbaum; H Zhang; J Cho; R C Verdonk; Teh Römkens; N G Venneman; I Kats; J M Vrolijk; Gjm Hemmink; A Otten; Acitl Tan; B J Elmunzer; P B Cotton; Jph Drenth; Ejm van Geenen
Journal:  United European Gastroenterol J       Date:  2019-02-27       Impact factor: 4.623

3.  Fee-based care is important for access to prompt treatment of hip fractures among veterans.

Authors:  Kelly K Richardson; Peter Cram; Mary Vaughan-Sarrazin; Peter J Kaboli
Journal:  Clin Orthop Relat Res       Date:  2013-01-16       Impact factor: 4.176

4.  Mortality and length of stay in a veterans affairs hospital and private sector hospitals serving a common market.

Authors:  Gary E Rosenthal; Mary Vaughan Sarrazin; Dwain L Harper; Susan M Fuehrer
Journal:  J Gen Intern Med       Date:  2003-08       Impact factor: 5.128

5.  Mortality of Department of Veterans Affairs patients undergoing coronary revascularization in private sector hospitals.

Authors:  Mary S Vaughan-Sarrazin; Bonnie Wakefield; Gary E Rosenthal
Journal:  Health Serv Res       Date:  2007-10       Impact factor: 3.402

6.  Variability in outcome and resource use in intensive care units.

Authors:  Hans U Rothen; Kay Stricker; Johanna Einfalt; Peter Bauer; Philip G H Metnitz; Rui P Moreno; Jukka Takala
Journal:  Intensive Care Med       Date:  2007-06-01       Impact factor: 41.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.